Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
GSK Agrees to Acquire Autoimmune Disease Treatment From Chimagen Biosciences
- Client News
- October 29, 2024
Paul, Weiss is advising UK-based GSK plc in its proposed acquisition of an investigational molecule used to treat autoimmune disease from Chimagen Biosciences, a China-based privately held biotechnology company. Under the terms of the agreement, GSK will pay $300 million up front to acquire the full global rights to the molecule, CMG1A46. Chimagen will also be eligible to receive success-based development and commercial milestone payments for CMG1A46 totaling $550 million.
GSK plans to develop and commercialize CMG1A46, with a focus on certain types of lupus, with potential to expand into related autoimmune diseases. The transaction is subject to customary closing conditions and regulatory approvals.
The Paul, Weiss team is led by partners Krishna Veeraraghavan, Benjamin Goodchild, Jonathan Ashtor and Bonnie Chen, and includes corporate partner Judie Ng Shortell and counsel Jack Sun; tax partner Cian O’Connor; and litigation partners Geoffrey Chepiga and Crystal Parker.